Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation
Conditions: NSCLC; EGFR Activating Mutation; Brain Metastases; Leptomeningeal Metastasis Intervention: Drug: TY-9591 Tablets Sponsor: TYK Medicines, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Lung Cancer | Neoplastic Meningitis | Neurology | Non-Small Cell Lung Cancer | Research | Study